Reports Q3 revenue $13.78M vs. $9.11M last year. The company’s cash, cash equivalents and marketable securities as of September 30, 2025, are now expected to fund operations into mid-2027 and through lonvo-z’s anticipated U.S. commercial launch for HAE.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics price target lowered to $4 from $9 at Baird
- Intellia Therapeutics: Hold Rating Amid Safety Concerns and Regulatory Challenges
- Intellia Therapeutics price target lowered to $12 from $17 at Wells Fargo
- Intellia Therapeutics price target lowered to $21 from $29 at Citizens JMP
- Intellia Therapeutics price target lowered to $14 from $24 at Barclays